Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluoxetine + simvastatin is a combination of two small molecule drugs, each with distinct mechanisms of action. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) primarily used to treat major depressive disorder, obsessive-compulsive disorder, bulimia nervosa, panic disorder, and premenstrual dysphoric disorder. It works by inhibiting the reuptake of serotonin in the brain, thereby increasing its availability in the synaptic cleft and enhancing serotonergic neurotransmission[1]. Simvastatin is an HMG-CoA reductase inhibitor (statin) used to lower lipid levels and reduce cardiovascular risk by inhibiting cholesterol biosynthesis in the liver[4]. The combination has been studied for potential synergistic effects on mood disorders and may provide anxiolytic and antidepressant properties according to animal studies[3]. There are pharmacokinetic interactions between these drugs; fluoxetine can increase serum concentrations of simvastatin due to CYP enzyme inhibition[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluoxetine + simvastatin.